Drawing for FELDAN

USPTO serial 79450804

FELDAN

Reviewed by CopyMark Law Group

Status 640Office Action
Filing date
Status date
Registration date
—
Examiner
KHAN, AHSEN M
Law office
TMO LAW OFFICE 113

What this means

The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.

Status 640: Status 640 means the examining attorney has prepared a non-final Office Action but it has not been mailed or e-mailed yet. The action should appear in TSDR soon, and a response deadline will start once it is issued.

Need help with FELDAN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases, chronic wound, skin cancer, precancerous skin lesions, skin fibrosis and treatment of acne; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases, disorders and infections; pharmaceutical preparations for treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), parkinson's disease, multiple sclerosis, myasthenia gravis, huntington's disease; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia and obesity; pharmaceutical preparations for the treatment of infectious diseases, namely respiratory infections, eye infections, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for use in hematology, namely for the treatment of blood disorders; pharmaceutical preparations for use in the treatment of musculoskeletal diseases and disorders; pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; cardiovascular pharmaceutical preparations; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; pharmaceutical preparations for the treatment of endocrine diseases, namely, glucagonoma; dermatological pharmaceutical preparations for the treatment of psoriasis; dermatological pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the diagnosis of oncological diseases and disorders; pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations.ACTIVE—
042Pharmaceutical research and development; research and development in the fields of pharmaceuticals, biotechnology, cell therapies, drug delivery technologies, dermatology, oncology, cardiology, gastroenterology, endocrinology, genitourinary, ophthalmology, nephrology, pulmonology, vascular system, and ischemia; providing medical scientific information in the fields of pharmaceuticals, biotechnology, cell therapies, drug delivery technologies, dermatology, oncology, cardiology, gastroenterology, endocrinology, genitourinary, ophthalmology, nephrology, pulmonology, vascular system, and ischemia; drug discovery services.ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 27, 2026RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jun 26, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 26, 2026DOCKASSIGNED TO EXAMINER—
Jun 5, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Jun 5, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 28, 2026REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance